The ups and downs of sirolimus in kidney transplantation, and the importance of reporting negative findings

Netherlands Journal of Medicine

Volumn 65, Issue 1, 2007, Pages 3-4

  van Gelder, T ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; BASILIXIMAB; CALCINEURIN INHIBITOR; CORTICOSTEROID; CREATININE; CYCLOSPORIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PLACEBO; RAPAMYCIN; STEROID;

ACUTE GRAFT REJECTION; CANCER RISK; CARDIOVASCULAR DISEASE; CLINICAL PROTOCOL; CLINICAL STUDY; CLINICAL TRIAL; CREATININE CLEARANCE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DRUG WITHDRAWAL; EDITORIAL; GRAFT DYSFUNCTION; GRAFT REJECTION; GRAFT SURVIVAL; HEALTH PRACTITIONER; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFORMED CONSENT; KIDNEY BIOPSY; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; LONG TERM CARE; LYMPHOCELE; NEPHROTOXICITY; PROTEINURIA; PUBLISHING; REGISTRATION; RISK REDUCTION; TREATMENT OUTCOME; VOLUNTARY REPORTING; WOUND HEALING IMPAIRMENT;

GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; SIROLIMUS;

EID: 33846552237     PISSN: 03002977     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (17)

1. Bardy AH. Bias in reporting clinical trials. Br J Clin Pharmacol 1998;46:147-50.
2. Dichersin K, Rennie D. Registering clinical trials. JAMA 2003;290:516-23.
3. Hooft L, Assendelft WJJ, Hoeksema HL, Scholten RJM. Een nationaal prospectief trialregister voor gerandomiseerde en gecontroleerde trials; ethisch en praktisch noodzakelijk. Ned Tijdschr Geneeskd 2004;148:1866-9.
4. Van den Akker JM, Hené RJ, Hoitsma AJ. Inferior results with basic immunosuppression with sirolimus in kidney transplantation. Neth J Med 2007;1:23-8.
5. Solez K, Vincenti F, Filo RS. Histopathological findings from 2-year protocol biopsies from a U.S. multicenter kidney transplant trial comparing tacrolimus versus cyclosporine. Transplantation 1998;66:1736-40.
6. MacDonald A, for the Rapamune global study group. A worldwide, phase III, randomized, controlled, safety and efficacy study of a sirolimus/ cyclosporine regimen for the prevention of acute rejection in recipients of primary mismatched renal allografts. Transplantation 2001;71:271-80.
7. Kahan BD, for the US Study Group. Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomized multicentre study. Lancet 2000;356:194-202.
8. Knight RJ, Kahan BD. The place of sirolimus in kidney transplantation: can we reduce calcineurin inhibitor renal toxicity? Kidney Int 2006;70:994-9.
9. Kreis H, Oberbauer R, Campistol JM, et al. Long term benefits with sirolimus-based therapy after kidney transplantation. J Am Soc Nephrol 2004;15:809-17.
10. McTaggart RA, Gottlieb D, Brooks J, et al. Sirolimus prolongs recovery from delayed graft function after cadaveric renal transplantation. Am J Transpl 2003;3:416-23.
11. Van den Akker, Wetzels JFM, Hoitsma AJ. Proteinuria following conversion from azathioprine to sirolimus in renal transplant recipients. Kidney Int 2006;70:1355-57.
12. Groth CG, Bäckman L, Morales JM, et al. Sirolimus (rapamycin)-based therapy in human renal transplantation. Transplantation 1999;67:1036-43.
13. Kreis H, Cisterne JM, Land W, et al. Sirolimus in association with mycophenolate mofetil induction for the prevention of acute rejection in renal allograft recipients. Transplantation 2000;69:1252-60.
14. Flechner SM, Goldfarb D, Modlin C, et al. Kidney transplantation without calcineurin inhibitor drugs: a prospective, randomized trial of sirolimus versus cyclosporine. Transplantation 2002;74:1070-6.
15. Flechner SM, Kurian S, Solez K, et al. De novo kidney transplantation without use of calcineurin inhibitors preserves renal structure and function at two years. Am J Transplant 2004;4:1776-85.
16. Ekberg H, Tedesco-Silva H, Demirbas A, et al. Symphony comparing standard immunosuppression to low-dose cyclosporine, tacrolimus or sirolimus in combination with MMF, daclizumab and corticosteroids in renal transplantation. Presented at World Transplant Congress, 2006, Boston, abstract 49.
17. Campistol JM, Eris J, Oberbauer R, et al. Sirolimus therapy early after cycloporine withdrawal reduces the risk for cancer in adult renal transplantation. J Am Soc Nephrol 2006;17:581-9.